Clinuvel Pharmaceuticals Limited

NasdaqGS:CUVL Stock Report

Market Cap: US$300.8m

Clinuvel Pharmaceuticals Past Earnings Performance

Past criteria checks 2/6

Clinuvel Pharmaceuticals has been growing earnings at an average annual rate of 9.8%, while the Biotechs industry saw earnings growing at 33.7% annually. Revenues have been growing at an average rate of 12.1% per year. Clinuvel Pharmaceuticals's return on equity is 12.4%, and it has net margins of 36.1%.

Key information

9.75%

Earnings growth rate

9.45%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate12.09%
Return on equity12.43%
Net Margin36.07%
Last Earnings Update30 Jun 2026

Recent past performance updates

Recent updates

Seeking Alpha • Sep 02

5 Reasons To Buy Clinuvel Pharmaceuticals After Its Nasdaq Uplisting

Summary Clinuvel Pharmaceuticals Limited is a profitable orphan-drug biotech with SCENESSE driving over 90% of revenue and exceptional margins. Despite flat growth in FY2026, CUVL maintains a strong balance sheet with A$252.1M in cash and no debt, funding expansion and R&D internally. The upcoming CUV105 vitiligo trial is a major catalyst; success could transform CUVL’s scale, but competition from AbbVie and Pfizer intensifies the risk. I rate CUVL stock a speculative Buy at 12x earnings, citing robust economics, cash optionality, and a high-impact pipeline, but highlight high risk if CUV105 disappoints. Read the full article on Seeking Alpha

Revenue & Expenses Breakdown

How Clinuvel Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:CUVL Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2694342018
31 Mar 2695332020
31 Dec 259633348
30 Sep 259634338
30 Jun 2595361821
31 Mar 2593372213
31 Dec 249139274
30 Sep 249037283
30 Jun 248836292
31 Mar 248533292
31 Dec 238230291
30 Sep 238030271
30 Jun 237831251
31 Mar 237429231
31 Dec 227026211
30 Sep 226824201
30 Jun 226621191
31 Mar 226222181
31 Dec 215724171
30 Sep 215324161
30 Jun 214825141
31 Mar 21432314-1
31 Dec 20382114-3
30 Sep 20351813-1
30 Jun 203315120
31 Mar 203215104
31 Dec 19321588
30 Sep 19321677
30 Jun 19311867
31 Mar 19291767
31 Dec 18271666
30 Sep 18261566
30 Jun 18251366
31 Mar 18211065
31 Dec 1717665
30 Sep 1717764
30 Jun 1717754
31 Mar 1714554
31 Dec 1612344
30 Sep 169044
30 Jun 167-354
31 Mar 165-533
31 Dec 154-623
30 Sep 154-843

Quality Earnings: CUVL has high quality earnings.

Growing Profit Margin: CUVL's current net profit margins (36.1%) are lower than last year (38.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CUVL's earnings have grown by 9.8% per year over the past 5 years.

Accelerating Growth: CUVL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CUVL had negative earnings growth (-6.2%) over the past year, making it difficult to compare to the Biotechs industry average (64.6%).

Return on Equity

High ROE: CUVL's Return on Equity (12.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/19 21:59
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2026/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Clinuvel Pharmaceuticals Limited is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Melissa BensonBarrenjoey Markets Pty Limited
Thomas WakimBell Potter
Madeleine WilliamsCanaccord Genuity